34104 research outputs found
Sort by
Debt Equity Swap : Case of Haseko Corporation
No full textはじめに 1.債務の株式化の仕組み 2.日本企業における導入動向 3.長谷工の事例 4.おわり
Research on the Ming Manuscript of the Yijian Zhi and the Established Text
No full textThe Yijian Zhi（夷堅志） is a collection of anecdotes about the supernatural complied by Hong Mai of the southern Song. The established text published by Zhonghua Shuju（中華書局）derives from the Southern Song Jian’an edition. The original printed version, the Kuaiji (會稽） edition, to which Hong Mai made revisions, is no longer in existence. According to Zhang Zhuping and my own research, the Ming manuscript of the Yijian zhi held by the Shanghai Library （referred to hereafter as Shanghai version B） has preserved the original unrevised text. Zhang Zhuping has pointed out that Shanghai version B and the established text differ. In this article, I compare the text of Shanghai version B with the Zhonghua Shuju version, focusing specifically on the differences not dealt with by Zhang Zhuping
An Study of the Novice Teacher’s Skill Development for the Latter among Colleagues in School
No full textⅠ.はじめに Ⅱ.分析に用いたデータ Ⅲ.分析結果の提示と考察 Ⅳ.おわり
直腸癌術後多発肝転移に対してSOX + Bevacizumab療法にてCRを得た1例
No full textAlthough chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and feasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete response (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection and additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple liver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated. Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver metastases could not be identified using CT after the end of the sixth course. Grade 1peripheral neuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was changed to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the regimen change.【はじめに】再発大腸癌の治慮法は，切除可能であれば，手術療法が第一選択であると考えられる．それが不可能な際は分子標的薬を含めた多剤併用による化学療法を選択するのが標準と考えられるが，化学療法のみでCRを得ることは困難である．【症例】67 歳男性．2013年1月にS状結腸癌に対してEMR を施行した．病理診断は，Adenocarcinoma in adenoma, Ip. Well differentiated adenocarcinoma in tubular adenoma with moderate atypia, invading into the submucosa, pSM(head invasion), ly1, v0, sprouting(+), INF alfa. The cut end is free of neoplastic tissue. そこで，同年3月にS状結腸切除術（D2郭清）を施行した．病理診断は，癌の遺残は認められず，最終的な進行度はSM,N0, H0, P0, M0 pStageI であった．2015年9 月，CTとMRI より多発肝転移が診断された．また，肺にも多発するすりガラス様陰影を認め，多発肺転移が疑われた． 2015年10月よりSOX + Bevacizumab 療法を開始した．Bevacizumab 7.5 mg/kgとOxaliplatin 130 mg/m^2をD1 に点滴投与し，S-1 120mg2x をD1-14 の2 週間服用した．その後1 週間休薬し，3 週間で1 コースとした．3 コース終了後の201 5 年1 2 月のCTにて肝再発巣は縮小を認めた．肺の病変は変化を認めず，腫瘍性変化より炎症性変化が疑われた．6 コース終了後の 2016 年3 月のCT では肝の転移巣は同定不能となった．治療期間中のside effect はgrade1の末梢神経障害だけであり，休薬や薬剤減量の必要はなかった．患者の経済的な理由よりその後はTS-1の服用に加療を変更した．2016 年6月と9月のCTでは病変の再出現を認めていない．【まとめ】今回，われわれは，SOX＋ Bevacizumab 療法による化学療法にてQOL を維持しながらCR を得た稀な大腸癌再発症例を経験したので報告した
Comprehensive Characterization of Mouse UDP-Glucuronosyltransferase (Ugt) Belonging to the Ugt2b Subfamily: Identification of Ugt2b36 as the Predominant Isoform Involved in Morphine Glucuronidation
No full textThe Effect of 2,3,7,8-Tetrafluorodibenzo-p-dioxin on Pubertal Rats : An Analysis Focusing on the Dioxin-like Acute Toxicity
No full textIt has long been believed that dioxins cause a number of acute toxicity such as body weight loss, hepatotoxicity and immunosuppression due to binding to the aryl hydrocarbon receptor (AHR). To propose provisions for these toxic effects, many researchers have challenged to identify the substances which are antagonistic to the AHR action. As the results, several compounds including polyphenols have been suggested to inhibit activation of AHR to ameliorate dioxin toxicity. However, none of them dramatically show protective effects on the living body. Therefore, developing revolutionary agents targeting the AHR remain to require for protecting our health from dioxin exposure. To address this issue, we newly synthesized 2,3,7,8-tetrafluorodibenzo-p-dioxin (TFDD), the product which chlorine atoms of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are replaced with fluorine atoms. Unlike with TCDD, a single oral administration of TFDD (1-1,000 μg/kg) to male pubertal rats hardly altered the hepatic activity of cytochrome P450 1A1 which is induced by AHR activation both one and seven days after treatment. In accordance with this, the suppression of body weight gain, hepatomegaly and thymic atrophy were not observed by TFDD treatment. However, TFDD slightly increased the weights of the lung and spleen, while the heart and kidney weights were slightly decreased by the treatment. These results suggest that an oral administration of TFDD does not have any dioxin-like acute toxicity, although some of tissues are influenced by TFDD at the higher doses
Therapeutic Strategies for yusho : History and Outlook for the Future
No full textThe Yusho incident is an unprecedented mass food poisoning that occurred in the western area of Japan in 1968. The causal rice bran oil contained a various dioxins and dioxins-like compounds (dioxins). No less than 2,000 people took orally the oil, and have suffered from characteristic mucocutaneous manifestations associated with non-specific systemic, respiratory, and neurological symptoms since its onset. Nowadays, the severe symptoms seen in the acute phase had faded in the majority of the patients ; however, there are the patients who have still suffered from various symptoms probably caused by dioxins retaining in the body. The Yusho Group has been researching effective treatments for Yusho patients. Several clinical trials that could accelerate the excretion of dioxins from the body had failed to relieve symptoms of yusho. Dioxins-induced toxicity is considered to be induced by activation of aryl hydrocarbon receptor (AHR) signaling pathway. It has been revealed that a variety of phytochemicals and herbal extracts possess biological activities that suppress AHR activation, which suggests that these chemicals might be promising candidates of therapy for Yusho patients. We here describe the history of therapeutic strategies for Yusho patients and discuss prospects for treatments